Milatuzumab
Milatuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against HLA class II histocompatibility antigen gamma chain.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Discoid lupus erythematosus | D008179 | L93.0 | 1 | — | — | — | — | 1 | |
| Lupus nephritis | D008181 | EFO_0005761 | 1 | — | — | — | — | 1 | |
| Central nervous system lupus vasculitis | D020945 | EFO_1001363 | 1 | — | — | — | — | 1 | |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MILATUZUMAB |
| INN | milatuzumab |
| Description | Milatuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 899796-83-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743040 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12943 |
| UNII ID | 2OP4E0GC6V (ChemIDplus, GSRS) |
Target
Agency Approved
CD74
CD74
Organism
Homo sapiens
Gene name
CD74
Gene synonyms
DHLAG
NCBI Gene ID
Protein name
HLA class II histocompatibility antigen gamma chain
Protein synonyms
CD74, CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated), CD74 molecule, major histocompatibility complex, class II invariant chain, class II MHC-associated invariant chain peptide, gamma chain of class II antigens, HLA-DR antigens-associated invariant chain, HLA-DR-gamma, Ia antigen-associated invariant chain, Ia-associated invariant chain, Ii, MHC HLA-DR gamma chain
Uniprot ID
Mouse ortholog
Cd74 (16149)
H-2 class II histocompatibility antigen gamma chain (P04441)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 278 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
686 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more